The Annual Cost of Defecation Disorders

Published Online: Tuesday, July 10, 2012
Follow Pharmacy_Times:
Fecal incontinence—the inability to control the passage of stool— is an expensive problem that can cost more than $4000 per person per year, according to a new study published in Diseases of the Colon & Rectum. The prevalence of fecal incontinence is expected to increase substantially as the elderly population continues to grow rapidly.

Investigators, led by senior author Dee E. Fenner, MD, Harold A. Furlong Professor of Women’s Health and codirector of the Michigan Bowel Control Program, calculated the hidden cost of complex defecation disorders. They examined 3 categories of expenses: direct medical cost (diagnosis, treatment and management of the condition), direct nonmedical cost (costs of nonmedical resources like protective products or transportation to care), and indirect cost, measured by loss of productivity.

Dr. Fenner concluded that because of its social stigma, too little attention is devoted to the treatment and prevention of fecal incontinence. In fact, this is the first US-based study to determine the condition’s per-patient cost.

“The disease is prevalent among men and women, and this study shows the cost is a significant burden to patients and to society,” she said.

To read more articles in this watch, click:
Flying Increases Risk of IBD Flares
T
he Annual Cost of Defecation Disorders


Related Articles
As providers of long-acting treatment injections, pharmacists can positively impact medication adherence.
The FDA today approved ruxolitinib to treat patients with polycythemia vera, a chronic type of bone marrow disease.
Sanofi and Regeneron Pharmaceutics, Inc, have convinced the FDA that their atopic dermatitis treatment works well enough to undergo accelerated development and regulatory review.
On the heels of the FDA approval of paliperidone palmitate as either a monotherapy or adjunctive therapy for schizoaffective disorder, Janssen Pharmaceuticals, Inc, has submitted a new drug application for the medication’s use as a 3-month atypical antipsychotic treatment for schizophrenia in adults.
Latest Issues
$auto_registration$